Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK

References

• World Health OrganizationChronic obstructive pulmonary disease (COPD). Fact sheet2016 Available from: http://www.who.int/media-centre/factsheets/fs315/en/Accessed June 2017
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease – 2018 Available from: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdfAccessed December 2017
   Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• HurstJRDonaldsonGCQuintJKGoldringJJBaghai-RavaryRWedzichaJATemporal clustering of exacerbations in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009179536937419074596
   PubMed Web of Science ®Google Scholar
• SuissaSDell’anielloSErnstPLong-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortalityThorax2012671195796322684094
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyRoflumilast. Summary of Product Characteristics18112016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001179/WC500095209.pdfAccessed June 2017
   Google Scholar
• Food and Drug AdministrationDaliresp (roflumilast) highlights of prescribing information2011 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022522s003lbl.pdfAccessed June 2017
   Google Scholar
• National Institute for Health and Care ExcellenceRoflumilast for treating chronic obstructive pulmonary disease2017 Available from: https://www.nice.org.uk/guidance/ta461Accessed August 27, 2018
   Google Scholar
• MartinezFJCalverleyPMGoehringUMBroseMFabbriLMRabeKFEffect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trialLancet2015385997185786625684586
   PubMed Web of Science ®Google Scholar
• MartinezFJRabeKFSethiSEffect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical TrialAm J Respir Crit Care Med2016194555956727585384
   PubMed Web of Science ®Google Scholar
• SamyshkinYKotchieRWMörkACBriggsAHBatemanEDCost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United KingdomEur J Health Econ2014151698223392624
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceAppraisal consultation document. Roflumilast for treating chronic obstructive pulmonary disease12017 Available from: https://www.nice.org.uk/guidance/GID-TA10062/documents/appraisal-consultation-documentAccessed June 2017
   Google Scholar
• CrapoROMorrisAHGardnerRMReference spirometric values using techniques and equipment that meet ATS recommendationsAm Rev Respir Dis198112366596647271065
   PubMed Web of Science ®Google Scholar
• TantucciCModinaDLung function decline in COPDInt J Chron Obstruct Pulmon Dis20127959922371650
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceGuide to the methods of technology appraisal2013 Available from: https://www.nice.org.uk/process/pmg9/chapter/forewordAccessed June 2017
   Google Scholar
• Joint Formulary CommitteeBritish National Formulary2016
   Google Scholar
• British Medical Journal. Best Practice. COPD2016 Available from: http://bestpractice.bmj.com/best-practice/monograph/7.htmlAccessed June 2017
   Google Scholar
• OostenbrinkJBRutten-van MölkenMPMonzBUFitzgeraldJMProbabilistic Markov model to assess the cost-effectiveness of broncho-dilator therapy in COPD patients in different countriesValue Health200581324615841892
   PubMed Web of Science ®Google Scholar
• CurtisLBurnsAUnit costs of health and social care. Canterbury: personal social services research unit2015 Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2015/Accessed June 2017
   Google Scholar
• Department of HealthNHS reference costs 2014–2015 Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477919/2014-15_Reference_costs_publication.pdfAccessed December 2017
   Google Scholar
• ThomasMRadwanAStonhamCMarshallSCOPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary careCOPD201411330030924152210
   PubMedGoogle Scholar
• Rutten-van MölkenMPOostenbrinkJBTashkinDPBurkhartDMonzBUDoes quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?Chest200613041117112817035446
   PubMed Web of Science ®Google Scholar
• HoogendoornMHoogenveenRTRutten-van MölkenMPVestboJFeenstraTLCase fatality of COPD exacerbations: a meta-analysis and statistical modelling approachEur Respir J201137350851520595157
   PubMed Web of Science ®Google Scholar
• National COPD Audit ProgrammeNational COPD Audit Programme. COPD: Who cares matters National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Clinical audit of COPD exacerbations admitted to acute units in England and Wales 2014. National clinical audit report2015 Available from: http://www.hqip.org.uk/public/cms/253/625/24/77/COPD%20National%20audit%20report%20-%20exacerbations%20-%202015.PDF?realName=zTtPO9.pdfAccessed August 27, 2018
   Google Scholar
• ConnollyMJLoweDAnsteyKAdmissions to hospital with exacerbations of chronic obstructive pulmonary disease: Effect of age related factors and service organisationThorax2006611084384816928716
   PubMed Web of Science ®Google Scholar
• RobertsCMLoweDBucknallCERylandIKellyYPearsonMGClinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary diseaseThorax200257213714111828043
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• HartlSLopez-CamposJLPozo-RodriguezFRisk of death and readmission of hospital-admitted COPD exacerbations: European COPD AuditEur Respir J201647111312126493806
   PubMed Web of Science ®Google Scholar
• WildmanMJSandersonCFGrovesJSurvival and quality of life for patients with COPD or asthma admitted to intensive care in a UK multicentre cohort: the COPD and Asthma Outcome Study (CAOS)Thorax200964212813218852157
   PubMed Web of Science ®Google Scholar